About Us

Semorex is a privately held U.S. based development-stage company with an R&D subsidiary, Semorex Technologies Ltd. based in Israel. Our core competency and proprietary technology in Selective Molecular Recognition enables us to develop novel targeted therapeutics for patients with cancer and protein-imprinted polymers for the elimination of specific proteins from the gastrointestinal tract hence improving the therapy of Crohn's disease.

These are markets with significant unmet needs and substantial growth potential. Semorex estimates that its lead product candidates have the potential to generate well in excess of $1 billion in revenues upon successful development.